Stay updated on CPX-351 and Quizartinib in AML Clinical Trial

Sign up to get notified when there's something new on the CPX-351 and Quizartinib in AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CPX-351 and Quizartinib in AML Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The page’s footer/test tooling label was updated from Revision v3.5.2 to v3.5.3, indicating a maintenance/version release rather than a change to the clinical trial record itself.
    Difference
    0.1%
    Check dated 2026-04-24T06:14:26.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    Added Revision: v3.5.2; Removed Revision: v3.5.0.
    Difference
    0.1%
    Check dated 2026-04-17T02:39:15.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    40 days ago
    Change Detected
    Summary
    The page footer now shows Revision: v3.5.0 (replacing v3.4.3). The overall record history content remains unchanged.
    Difference
    0.1%
    Check dated 2026-03-19T04:52:52.000Z thumbnail image
  5. Check
    47 days ago
    Change Detected
    Summary
    Added Revision: v3.4.3; Deleted Revision: v3.4.2.
    Difference
    0.1%
    Check dated 2026-03-12T00:38:16.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    A new version entry was added to the Record History, reflecting updated study status and recent changes to the record.
    Difference
    0.1%
    Check dated 2026-02-25T18:40:18.000Z thumbnail image
  7. Check
    75 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 to the record history; removed the government-funding/operating-status notice and the previous Revision: v3.4.1 entry.
    Difference
    0.7%
    Check dated 2026-02-11T14:08:35.000Z thumbnail image

Stay in the know with updates to CPX-351 and Quizartinib in AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CPX-351 and Quizartinib in AML Clinical Trial page.